Literature DB >> 35861924

Antiseizure Drugs and Movement Disorders.

Michel Sáenz-Farret1, Marina A J Tijssen2,3, Dawn Eliashiv4, Robert S Fisher5, Kapil Sethi6, Alfonso Fasano7,8,9.   

Abstract

The relationship between antiseizure drugs and movement disorders is complex and not adequately reviewed so far. Antiseizure drugs as a treatment for tremor and other entities such as myoclonus and restless leg syndrome is the most common scenario, although the scientific evidence supporting their use is variable. However, antiseizure drugs also represent a potential cause of iatrogenic movement disorders, with parkinsonism and tremor the most common disorders. Many other antiseizure drug-induced movement disorders are possible and not always correctly identified. This review was conducted by searching for all the possible combinations between 15 movement disorders (excluding ataxia) and 24 antiseizure drugs. The main objective was to describe the movement disorders treated and worsened or induced by antiseizure drugs. We also summarized the proposed mechanisms and risk factors involved in the complex interaction between antiseizure drugs and movement disorders. Antiseizure drugs mainly used to treat movement disorders are clonazepam, gabapentin, lacosamide, levetiracetam, oxcarbazepine, perampanel, phenobarbital, pregabalin, primidone, topiramate, and zonisamide. Antiseizure drugs that worsen or induce movement disorders are cenobamate, ethosuximide, felbamate, lamotrigine, phenytoin, tiagabine, and vigabatrin. Antiseizure drugs with a variable effect on movement disorders are carbamazepine and valproate while no effect on movement disorders has been reported for brivaracetam, eslicarbazepine, lacosamide, and stiripentol. Although little information is available on the adverse effects or benefits on movement disorders of newer antiseizure drugs (such as brivaracetam, cenobamate, eslicarbazepine, lacosamide, and rufinamide), the evidence collected in this review should guide the choice of antiseizure drugs in patients with concomitant epilepsy and movement disorders. Finally, these notions can lead to a better understanding of the mechanisms involved in the pathophysiology and treatments of movement disorders.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35861924     DOI: 10.1007/s40263-022-00937-x

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   6.497


  183 in total

1.  Quantitative comparison of barbiturates in essential hand and head tremor.

Authors:  E Sasso; E Perucca; R Fava; S Calzetti
Journal:  Mov Disord       Date:  1991       Impact factor: 10.338

Review 2.  Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France.

Authors:  Emmanuelle Bondon-Guitton; Santiago Perez-Lloret; Haleh Bagheri; Christine Brefel; Olivier Rascol; Jean-Louis Montastruc
Journal:  Mov Disord       Date:  2011-06-14       Impact factor: 10.338

3.  Phenytoin-related ataxia in patients with epilepsy: clinical and radiological characteristics.

Authors:  Priya D Shanmugarajah; Nigel Hoggard; Daniel P Aeschlimann; Pascale C Aeschlimann; Gary J Dennis; Stephen J Howell; Markus Reuber; Richard A Grünewald; Marios Hadjivassiliou
Journal:  Seizure       Date:  2018-02-02       Impact factor: 3.184

Review 4.  Management of patients with myoclonus: available therapies and the need for an evidence-based approach.

Authors:  Joke M Dijk; Marina A J Tijssen
Journal:  Lancet Neurol       Date:  2010-10       Impact factor: 44.182

Review 5.  Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.

Authors:  Gaetano Zaccara; Fabio Giovannelli; Dario Maratea; Valeria Fadda; Alberto Verrotti
Journal:  Seizure       Date:  2013-04-25       Impact factor: 3.184

Review 6.  Seizures and movement disorders: phenomenology, diagnostic challenges and therapeutic approaches.

Authors:  Maria Eliza Freitas; Marta Ruiz-Lopez; Josep Dalmau; Roberto Erro; Michael Privitera; Danielle Andrade; Alfonso Fasano
Journal:  J Neurol Neurosurg Psychiatry       Date:  2019-02-22       Impact factor: 10.154

7.  Phenobarbital and propranolol in essential tremor: a double-blind controlled clinical trial.

Authors:  A Baruzzi; G Procaccianti; P Martinelli; R Riva; F Denoth; N Montanaro; E Lugaresi
Journal:  Neurology       Date:  1983-03       Impact factor: 9.910

8.  Orthostatic tremor: successful treatment with phenobarbital.

Authors:  F Cabrera-Valdivia; F J Jiménez-Jiménez; E García Albea; J Tejeiro-Martínez; J A Vaquero Ruipérez; L Ayuso-Peralta
Journal:  Clin Neuropharmacol       Date:  1991-10       Impact factor: 1.592

9.  Movement disorders phenomenology in focal motor seizures.

Authors:  Alfonso Fasano; Carlo Di Bonaventura; Francesco Bove; Alberto J Espay; Francesca Morgante; Giovanni Fabbrini; Renato P Munhoz; Danielle Andrade; Felipe Borlot; Esther Bui; Giancarlo Di Gennaro; Raffaele Iorio; Hans Katzberg; Marco Luigetti; Pasquale Striano; Giovanni Defazio; Alfredo Berardelli
Journal:  Parkinsonism Relat Disord       Date:  2018-10-16       Impact factor: 4.891

10.  Genetic Neonatal-Onset Epilepsies and Developmental/Epileptic Encephalopathies with Movement Disorders: A Systematic Review.

Authors:  Carlotta Spagnoli; Carlo Fusco; Antonio Percesepe; Vincenzo Leuzzi; Francesco Pisani
Journal:  Int J Mol Sci       Date:  2021-04-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.